Cosmos Health Actively Exploring Spinoff of R&D Division into a Publicly Listed Standalone Biotech Company
CHICAGO, IL / ACCESSWIRE / September 27, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
COVID-19
Scilex Holding Company Submits a Request to the Securities and Exchange Commission to Withdraw its Registration Statement on Form S-1 (File No. 333-271401)
PALO ALTO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating...
Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting
Abstract titles to be presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting were released publicly today at...
Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials...
Microbot Medical Engages CRO to Support its Upcoming U.S. Pivotal Clinical Trial
The engagement is an additional step in the Company's path towards marketing clearance with the FDABRAINTREE, Mass., Sept. 27, 2023...
Tonix Pharmaceuticals Announces Department of Defense Grant to Support the University of North Carolina’s Proposed Investigator Sponsored OASIS Trial of TNX-102 SL for Treatment of Acute Stress Reaction, Acute Stress Disorder, and Posttraumatic Stress Disorder
$3 million awarded by DoD to University of North Carolina Institute of Trauma Recovery to support a proposed 180-patient, randomized,...
Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology
Clinical trial evaluating the Company’s novel mRNA biomarkers demonstrated sensitivity for colorectal cancer of 94% with specificity of 97% and...
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents
RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024FARMINGTON HILLS, Mich., and PITTSBURGH, Sept....
Akari Therapeutics to Present at Emerging Growth Conference
BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced...
Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
SAN DIEGO, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform...
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be...
Globus Medical and NuVasive to Sponsor and Participate at EUROSPINE 2023
AUDUBON, Pa., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced...
Therma Bright Announces Amendments to InStatin & InVixa Acquisitions
InStatin & InVixa Are Developing Novel Treatments for COVID-19, Asthma, and Chronic Obstructive Pulmonary Disease (COPD)Toronto, Ontario--(Newsfile Corp. - September...
Advanced Health Intelligence to Play a Pivotal Role in Bearn Collaboration with AIG Insurance
HighlightsAHI partner Bearn LLC ("Bearn") signs transformative commercial partnership with US insurance conglomerate American International Group Inc. ("AIG").AHI biometrics to...
Cosmos Health Announces Expansion of Its C-Sept Brand with the Launch of C-Scrub Wash; Capitalizing on $29 Billion Global Antiseptic and Disinfectant Market
CHICAGO, IL / ACCESSWIRE / September 26, 2023 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified,...
Biogen Completes Acquisition of Reata Pharmaceuticals
Reata acquisition bolsters Biogen’s rare disease portfolio with the addition of SKYCLARYS® (omaveloxolone), the first and only FDA approved treatment...
Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells
JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA")...
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)
--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult...
IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies
Provides a look at the new manufacturing facility in Huntsville, Alabama Introduced as part of IMUNON's newly relaunched website LAWRENCEVILLE,...
Taysha Gene Therapies Announces Second Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Adult Trial for the Treatment of Rett Syndrome
Available clinical data from the two adult patients dosed with TSHA-102 in the first cohort (low dose) to be discussed...